Literature DB >> 31448432

Efficacy and safety of axitinib for metastatic renal cell carcinoma in patients on hemodialysis for end-stage renal disease: Case series of eight patients.

Hiroki Ishihara1, Toshio Takagi1, Tsunenori Kondo2, Kazuhiko Yoshida1, Masayoshi Okumi1, Kazunari Tanabe1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31448432     DOI： 10.1111/iju.14093

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


× No keyword cloud information.
  4 in total

1.  Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.

Authors:  Hiroki Ishihara; Hironori Fukuda; Hidekazu Tachibana; Kazuhiko Yoshida; Hirohito Kobayashi; Toshio Takagi; Junpei Iizuka; Hideki Ishida; Yoji Nagashima; Tsunenori Kondo; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2021-02-27       Impact factor: 2.801

Review 2.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.

Authors:  Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

3.  Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report.

Authors:  Yuki Katsumata; Yoshihide Kawasaki; Kayu Tanaka; Daisuke Nakayama; Hiromichi Katayama; Shuichi Shimada; Yohei Satake; Takuma Sato; Naoki Kawamorita; Shinichi Yamashita; Testuya Sato; Kosuke Shoji; Koji Mitsuzuka; Akihiro Ito
Journal:  Case Rep Oncol       Date:  2021-10-22

4.  Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease.

Authors:  Hiroki Ishihara; Satoshi Yamashita; Yu-Yu Liu; Naoko Hattori; Omar El-Omar; Takashi Ikeda; Hironori Fukuda; Kazuhiko Yoshida; Toshio Takagi; Sekiko Taneda; Tsunenori Kondo; Yoji Nagashima; Kazunari Tanabe; Toshikazu Ushijima
Journal:  Cancer Sci       Date:  2020-09-18       Impact factor: 6.716
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.